Maryland State Retirement & Pension System Sells 212 Shares of Glaukos Co. (NYSE:GKOS)

Maryland State Retirement & Pension System trimmed its position in shares of Glaukos Co. (NYSE:GKOS) by 1.2% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 17,707 shares of the medical instruments supplier’s stock after selling 212 shares during the quarter. Maryland State Retirement & Pension System’s holdings in Glaukos were worth $1,408,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds also recently modified their holdings of GKOS. Fred Alger Management LLC grew its holdings in Glaukos by 9.2% during the 3rd quarter. Fred Alger Management LLC now owns 1,780,690 shares of the medical instruments supplier’s stock worth $133,997,000 after acquiring an additional 150,102 shares during the last quarter. Invesco Ltd. grew its stake in shares of Glaukos by 45.5% during the third quarter. Invesco Ltd. now owns 1,450,033 shares of the medical instruments supplier’s stock valued at $109,115,000 after purchasing an additional 453,756 shares during the last quarter. Primecap Management Co. CA increased its holdings in shares of Glaukos by 3.3% in the third quarter. Primecap Management Co. CA now owns 638,620 shares of the medical instruments supplier’s stock valued at $48,056,000 after purchasing an additional 20,120 shares in the last quarter. Northern Trust Corp raised its position in Glaukos by 0.5% in the 3rd quarter. Northern Trust Corp now owns 552,317 shares of the medical instruments supplier’s stock worth $41,562,000 after purchasing an additional 2,490 shares during the last quarter. Finally, New York State Common Retirement Fund lifted its holdings in Glaukos by 0.4% during the 4th quarter. New York State Common Retirement Fund now owns 513,029 shares of the medical instruments supplier’s stock worth $40,781,000 after buying an additional 1,867 shares in the last quarter. Institutional investors and hedge funds own 99.04% of the company’s stock.

Glaukos Trading Down 1.0 %

GKOS opened at $106.91 on Thursday. Glaukos Co. has a twelve month low of $54.38 and a twelve month high of $110.73. The firm has a market cap of $5.38 billion, a PE ratio of -37.12 and a beta of 1.08. The company has a debt-to-equity ratio of 0.78, a quick ratio of 4.68 and a current ratio of 5.38. The firm’s fifty day moving average is $94.28 and its two-hundred day moving average is $83.79.

Glaukos (NYSE:GKOS) last posted its earnings results on Wednesday, May 1st. The medical instruments supplier reported ($0.70) earnings per share for the quarter, missing the consensus estimate of ($0.58) by ($0.12). Glaukos had a negative return on equity of 24.69% and a negative net margin of 43.15%. The business had revenue of $85.60 million for the quarter, compared to the consensus estimate of $79.60 million. During the same quarter in the prior year, the firm posted ($0.59) earnings per share. The business’s revenue was up 15.8% on a year-over-year basis. Equities research analysts anticipate that Glaukos Co. will post -2.2 EPS for the current year.

Insider Activity at Glaukos

In other Glaukos news, CFO Alex R. Thurman sold 474 shares of the firm’s stock in a transaction that occurred on Tuesday, April 2nd. The shares were sold at an average price of $90.37, for a total transaction of $42,835.38. Following the sale, the chief financial officer now directly owns 54,916 shares in the company, valued at approximately $4,962,758.92. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. In related news, CFO Alex R. Thurman sold 434 shares of the stock in a transaction dated Thursday, April 4th. The stock was sold at an average price of $95.33, for a total transaction of $41,373.22. Following the completion of the transaction, the chief financial officer now directly owns 54,166 shares in the company, valued at $5,163,644.78. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, CFO Alex R. Thurman sold 474 shares of the business’s stock in a transaction that occurred on Tuesday, April 2nd. The shares were sold at an average price of $90.37, for a total value of $42,835.38. Following the completion of the sale, the chief financial officer now owns 54,916 shares in the company, valued at approximately $4,962,758.92. The disclosure for this sale can be found here. In the last three months, insiders sold 230,544 shares of company stock worth $21,767,497. 6.40% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

GKOS has been the subject of a number of recent research reports. StockNews.com downgraded Glaukos from a “hold” rating to a “sell” rating in a research report on Tuesday, February 27th. Citigroup upped their target price on shares of Glaukos from $107.00 to $120.00 and gave the company a “buy” rating in a research report on Monday, March 25th. Stifel Nicolaus reiterated a “buy” rating and set a $110.00 price target on shares of Glaukos in a research report on Wednesday, April 3rd. Jefferies Financial Group upgraded shares of Glaukos from a “hold” rating to a “buy” rating and increased their price objective for the company from $84.00 to $125.00 in a report on Monday. Finally, Mizuho lifted their target price on shares of Glaukos from $85.00 to $100.00 and gave the stock a “neutral” rating in a report on Thursday, April 11th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and nine have assigned a buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $108.64.

Glaukos Profile

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.